News | 01 December 2024
Dr. Reddy's launches Toripalimab in India
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The product will be marketed by Dr. Reddy's
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Modernization and supply chain diversity drive new growth
Subscribe To Our Newsletter & Stay Updated
